Table 3 Patients reporting ≥1 antibiotic by class, and mean duration of antibiotic use, for patients administered antibiotics under Prescribing Scenario C and Scenario B/C- by patient status and country

Patients prescribed antibiotics according to Scenario C, N

–

1

–

–

–

1

2

2

2

1

9

16

Mean (95% CI) duration of use of antibiotics, Scenario C, days

–

7.0 (3.3, 14.7)

–

–

–

7.0 (3.3, 14.7)

6.0 (3.4,10.6)

5.5 (3.0, 9.9)

5.5 (3.0, 9.9)

5.0 (2.1, 12.0)

5.4 (4.1, 7.2)

5.5 (4.2, 7.2)

 β-lactam agent

–

1 (100.0)

–

–

–

1 (100.0)

1 (50.0)

2 (100.0)

2 (100.0)

1 (100.0)

8 (88.9)

14 (87.5)

 Aminoglycide

–

–

–

–

–

–

1 (50.0)

–

1 (50.0)

–

–

2 (12.5)

 Lincosamide

–

–

–

–

–

–

1 (50.0)

1 (50.0)

1 (50.0)

–

–

3 (18.8)

 Macrolide

–

–

–

–

–

–

–

–

–

–

1 (11.1)

1 (6.3)

Patients prescribed antibiotics according to Scenario B/C, N

16

2

6

17

8

49

50

40

49

54

38

231

Mean (95% CI) duration of use of antibiotics, Scenario B/C, days

9.5 (8.0, 11.2)

7.0 (4.1, 11.8)

8.2 (6.2, 10.8)

6.5 (5.4, 7.8)

8.5 (6.7,10.8)

7.9 (6.8, 9.0)

8.9 (8.1, 9.8)

7.2 (6.4,8.1)

15.8 (14.8, 17.0)

14.9 (13.9, 16.0)

8.1 (7.3, 9.1)

10.4 (10.0, 10.9)

 β-lactam agent

15 (93.8)

2 (100.0)

4 (66.7)

12 (70.6)

7 (87.5)

40 (81.6)

28 (56.0)

38 (95.0)

44 (89.8)

54 (100.0)

34 (84.5)

198 (85.7)

 Lincosamide

6 (37.5)

–

3 (50.0)

–

–

9 (18.4)

35 (70.0)

6 (15.0)

29 (59.2)

24 (44.4)

3 (7.9)

97(42.0)

 Aminoglycide

–

–

–

1 (5.9)

–

1 (100.0)

5 (10.0)

6 (15.0)

5 (10.2)

1 (1.9)

1 (2.6)

18 (7.8)

 Glycopeptide

–

–

–

–

–

–

2 (4.0)

–

8 (16.3)

4 (7.4)

1 (2.6)

15 (6.5)

 Other

6 (37.5)

–

1 (16.7)

5 (29.4)

1 (12.5)

13 (26.5)

11 (22.0)

–

3 (6.1)

1 (1.9)

1 (2.6)

15 (6.5)

 Macrolide

–

–

–

1 (5.9)

1 (12.5)

2 (4.1)

–

–

1 (2.0)

–

3 (7.9)

4 (17.3)

 Fluoroquinolone

–

–

–

–

–

–

–

1 (2.5)

2 (4.0)

–

1 (2.6)

4 (1.7)